The Experts below are selected from a list of 81 Experts worldwide ranked by ideXlab platform
Cindy K Cook - One of the best experts on this subject based on the ideXlab platform.
-
a subgroup analysis in hispanic patients with allergic rhinitis of fluticasone propionate aqueous nasal spray for Sinus Pain and pressure caused by nasal congestion
The Journal of Allergy and Clinical Immunology, 2004Co-Authors: Cindy K Cook, Barbara A Prillaman, Edward E Philpot, Kathy RickardAbstract:Abstract Rationale Sinus Pain and pressure (SP+P) is a common symptom of allergic rhinitis. Fluticasone propionate aqueous nasal spray (FP) has been shown to reduce SP+P associated with allergies. Most research studies report findings for Caucasian and African American subgroups. Few research studies report findings for Hispanic patients, a growing population in the United States. Methods Two multi-center, double-blind, placebo-controlled, parallel-group studies compared daily dosing of FP 200μg (FP200QD) or placebo in 401 patients (age 12-74) with moderate-to-severe SP+P and nasal congestion. Of these, 115 Hispanic patients received either FP200QD (n=53) or placebo (n=62). Patients used a 100mm visual analog scale each evening to assess the severity of SP+P experienced over the day. Mean change from baseline for SP+P was determined over the 14-day treatment period. Descriptive statistics were displayed for the Hispanic subgroup and the magnitude of improvement was compared to the total population. Results Mean (SE) SP+P scores at baseline were similar for the total populations and Hispanic subgroups ranging from 71.0 (1.98) to 80.3 (2.10). Over the 14-day treatment period, mean changes (SE) from baseline in Study FNM40184 and FNM40185, respectively, were -19.6 (2.41) and -17.8 (2.10) for placebo compared with -26.4 (2.20) and -27.8 (2.41) for FP200QD in the total population (p Conclusions These studies suggest that FP200QD improves Sinus Pain and pressure in Hispanic patients with allergic rhinitis.
-
relief of Sinus Pain and pressure with fluticasone propionate aqueous nasal spray a placebo controlled trial in patients with allergic rhinitis
Allergy and asthma proceedings : the official journal of regional and state allergy societies, 2002Co-Authors: Paul H Ratner, William C Howland, Robert L Jacobs, Kenneth D Reed, S T Goodesellers, Barbara A Prillaman, Edward E Philpot, Cindy K CookAbstract:Although allergic rhinitis is commonly associated most with symptoms of nasal congestion, rhinorrhea, sneezing, and itching, the symptom of Sinus Pain and pressure often prompts the patient to seek medical attention. The effect of fluticasone propionate on this symptom has not been studied. The purpose of this study was to compare the efficacy and safety of fluticasone propionate aqueous nasal spray to placebo vehicle in the treatment of patients with Sinus Pain and pressure arising from allergic rhinitis. A multicenter, double-blind, parallel-group trial was conducted in 206 symptomatic patients > or = 12 years with seasonal or perennial allergic rhinitis. Patients were treated for 14 days with either fluticasone propionate aqueous nasal spray, 200 mcg once daily, or placebo vehicle. Patients attended clinic visits and kept diary cards rating Sinus Pain and pressure (measured as one symptom) and nasal congestion symptoms during the study. Treatment with fluticasone propionate provided significantly greater relief of symptoms of Sinus Pain and pressure compared with placebo over the entire 14-day treatment period. Nasal congestion scores also were significantly reduced compared with placebo at each time point. Treatments were well tolerated, and the incidence of adverse events attributable to study treatments was similar between groups. Our data indicate that symptoms of Sinus Pain and pressure and nasal congestion can be significantly reduced in patients with allergic rhinitis when treated with fluticasone propionate aqueous nasal spray, 200 mcg once daily.
Kathy Rickard - One of the best experts on this subject based on the ideXlab platform.
-
a subgroup analysis in hispanic patients with allergic rhinitis of fluticasone propionate aqueous nasal spray for Sinus Pain and pressure caused by nasal congestion
The Journal of Allergy and Clinical Immunology, 2004Co-Authors: Cindy K Cook, Barbara A Prillaman, Edward E Philpot, Kathy RickardAbstract:Abstract Rationale Sinus Pain and pressure (SP+P) is a common symptom of allergic rhinitis. Fluticasone propionate aqueous nasal spray (FP) has been shown to reduce SP+P associated with allergies. Most research studies report findings for Caucasian and African American subgroups. Few research studies report findings for Hispanic patients, a growing population in the United States. Methods Two multi-center, double-blind, placebo-controlled, parallel-group studies compared daily dosing of FP 200μg (FP200QD) or placebo in 401 patients (age 12-74) with moderate-to-severe SP+P and nasal congestion. Of these, 115 Hispanic patients received either FP200QD (n=53) or placebo (n=62). Patients used a 100mm visual analog scale each evening to assess the severity of SP+P experienced over the day. Mean change from baseline for SP+P was determined over the 14-day treatment period. Descriptive statistics were displayed for the Hispanic subgroup and the magnitude of improvement was compared to the total population. Results Mean (SE) SP+P scores at baseline were similar for the total populations and Hispanic subgroups ranging from 71.0 (1.98) to 80.3 (2.10). Over the 14-day treatment period, mean changes (SE) from baseline in Study FNM40184 and FNM40185, respectively, were -19.6 (2.41) and -17.8 (2.10) for placebo compared with -26.4 (2.20) and -27.8 (2.41) for FP200QD in the total population (p Conclusions These studies suggest that FP200QD improves Sinus Pain and pressure in Hispanic patients with allergic rhinitis.
Edward E Philpot - One of the best experts on this subject based on the ideXlab platform.
-
a subgroup analysis in hispanic patients with allergic rhinitis of fluticasone propionate aqueous nasal spray for Sinus Pain and pressure caused by nasal congestion
The Journal of Allergy and Clinical Immunology, 2004Co-Authors: Cindy K Cook, Barbara A Prillaman, Edward E Philpot, Kathy RickardAbstract:Abstract Rationale Sinus Pain and pressure (SP+P) is a common symptom of allergic rhinitis. Fluticasone propionate aqueous nasal spray (FP) has been shown to reduce SP+P associated with allergies. Most research studies report findings for Caucasian and African American subgroups. Few research studies report findings for Hispanic patients, a growing population in the United States. Methods Two multi-center, double-blind, placebo-controlled, parallel-group studies compared daily dosing of FP 200μg (FP200QD) or placebo in 401 patients (age 12-74) with moderate-to-severe SP+P and nasal congestion. Of these, 115 Hispanic patients received either FP200QD (n=53) or placebo (n=62). Patients used a 100mm visual analog scale each evening to assess the severity of SP+P experienced over the day. Mean change from baseline for SP+P was determined over the 14-day treatment period. Descriptive statistics were displayed for the Hispanic subgroup and the magnitude of improvement was compared to the total population. Results Mean (SE) SP+P scores at baseline were similar for the total populations and Hispanic subgroups ranging from 71.0 (1.98) to 80.3 (2.10). Over the 14-day treatment period, mean changes (SE) from baseline in Study FNM40184 and FNM40185, respectively, were -19.6 (2.41) and -17.8 (2.10) for placebo compared with -26.4 (2.20) and -27.8 (2.41) for FP200QD in the total population (p Conclusions These studies suggest that FP200QD improves Sinus Pain and pressure in Hispanic patients with allergic rhinitis.
-
relief of Sinus Pain and pressure with fluticasone propionate aqueous nasal spray a placebo controlled trial in patients with allergic rhinitis
Allergy and asthma proceedings : the official journal of regional and state allergy societies, 2002Co-Authors: Paul H Ratner, William C Howland, Robert L Jacobs, Kenneth D Reed, S T Goodesellers, Barbara A Prillaman, Edward E Philpot, Cindy K CookAbstract:Although allergic rhinitis is commonly associated most with symptoms of nasal congestion, rhinorrhea, sneezing, and itching, the symptom of Sinus Pain and pressure often prompts the patient to seek medical attention. The effect of fluticasone propionate on this symptom has not been studied. The purpose of this study was to compare the efficacy and safety of fluticasone propionate aqueous nasal spray to placebo vehicle in the treatment of patients with Sinus Pain and pressure arising from allergic rhinitis. A multicenter, double-blind, parallel-group trial was conducted in 206 symptomatic patients > or = 12 years with seasonal or perennial allergic rhinitis. Patients were treated for 14 days with either fluticasone propionate aqueous nasal spray, 200 mcg once daily, or placebo vehicle. Patients attended clinic visits and kept diary cards rating Sinus Pain and pressure (measured as one symptom) and nasal congestion symptoms during the study. Treatment with fluticasone propionate provided significantly greater relief of symptoms of Sinus Pain and pressure compared with placebo over the entire 14-day treatment period. Nasal congestion scores also were significantly reduced compared with placebo at each time point. Treatments were well tolerated, and the incidence of adverse events attributable to study treatments was similar between groups. Our data indicate that symptoms of Sinus Pain and pressure and nasal congestion can be significantly reduced in patients with allergic rhinitis when treated with fluticasone propionate aqueous nasal spray, 200 mcg once daily.
Barbara A Prillaman - One of the best experts on this subject based on the ideXlab platform.
-
a subgroup analysis in hispanic patients with allergic rhinitis of fluticasone propionate aqueous nasal spray for Sinus Pain and pressure caused by nasal congestion
The Journal of Allergy and Clinical Immunology, 2004Co-Authors: Cindy K Cook, Barbara A Prillaman, Edward E Philpot, Kathy RickardAbstract:Abstract Rationale Sinus Pain and pressure (SP+P) is a common symptom of allergic rhinitis. Fluticasone propionate aqueous nasal spray (FP) has been shown to reduce SP+P associated with allergies. Most research studies report findings for Caucasian and African American subgroups. Few research studies report findings for Hispanic patients, a growing population in the United States. Methods Two multi-center, double-blind, placebo-controlled, parallel-group studies compared daily dosing of FP 200μg (FP200QD) or placebo in 401 patients (age 12-74) with moderate-to-severe SP+P and nasal congestion. Of these, 115 Hispanic patients received either FP200QD (n=53) or placebo (n=62). Patients used a 100mm visual analog scale each evening to assess the severity of SP+P experienced over the day. Mean change from baseline for SP+P was determined over the 14-day treatment period. Descriptive statistics were displayed for the Hispanic subgroup and the magnitude of improvement was compared to the total population. Results Mean (SE) SP+P scores at baseline were similar for the total populations and Hispanic subgroups ranging from 71.0 (1.98) to 80.3 (2.10). Over the 14-day treatment period, mean changes (SE) from baseline in Study FNM40184 and FNM40185, respectively, were -19.6 (2.41) and -17.8 (2.10) for placebo compared with -26.4 (2.20) and -27.8 (2.41) for FP200QD in the total population (p Conclusions These studies suggest that FP200QD improves Sinus Pain and pressure in Hispanic patients with allergic rhinitis.
-
relief of Sinus Pain and pressure with fluticasone propionate aqueous nasal spray a placebo controlled trial in patients with allergic rhinitis
Allergy and asthma proceedings : the official journal of regional and state allergy societies, 2002Co-Authors: Paul H Ratner, William C Howland, Robert L Jacobs, Kenneth D Reed, S T Goodesellers, Barbara A Prillaman, Edward E Philpot, Cindy K CookAbstract:Although allergic rhinitis is commonly associated most with symptoms of nasal congestion, rhinorrhea, sneezing, and itching, the symptom of Sinus Pain and pressure often prompts the patient to seek medical attention. The effect of fluticasone propionate on this symptom has not been studied. The purpose of this study was to compare the efficacy and safety of fluticasone propionate aqueous nasal spray to placebo vehicle in the treatment of patients with Sinus Pain and pressure arising from allergic rhinitis. A multicenter, double-blind, parallel-group trial was conducted in 206 symptomatic patients > or = 12 years with seasonal or perennial allergic rhinitis. Patients were treated for 14 days with either fluticasone propionate aqueous nasal spray, 200 mcg once daily, or placebo vehicle. Patients attended clinic visits and kept diary cards rating Sinus Pain and pressure (measured as one symptom) and nasal congestion symptoms during the study. Treatment with fluticasone propionate provided significantly greater relief of symptoms of Sinus Pain and pressure compared with placebo over the entire 14-day treatment period. Nasal congestion scores also were significantly reduced compared with placebo at each time point. Treatments were well tolerated, and the incidence of adverse events attributable to study treatments was similar between groups. Our data indicate that symptoms of Sinus Pain and pressure and nasal congestion can be significantly reduced in patients with allergic rhinitis when treated with fluticasone propionate aqueous nasal spray, 200 mcg once daily.
Jayakar V Nayak - One of the best experts on this subject based on the ideXlab platform.
-
microcurrent technology for rapid relief of Sinus Pain a randomized placebo controlled double blinded clinical trial
International Forum of Allergy & Rhinology, 2019Co-Authors: Ximena A Maul, Nicole A Borchard, Peter H Hwang, Jayakar V NayakAbstract:Background Transcutaneous electrical nerve stimulation has proven to be effective in alleviating chronic Pain from facial myalgias. We evaluated the efficacy of a novel handheld microcurrent-emitting device in short-term, office-based treatment of patients with Sinus Pain. This device, which is U.S. Food and Drug Administration (FDA)-cleared, detects and treats regions corresponding to nerve fibers. Methods Randomized, double-blinded, placebo-controlled trial. Seventy-one participants with facial Pain attributed to self-reported nasal/Sinus disease were recruited from a tertiary rhinologic practice and the surrounding community and randomly assigned to either office-based use of an active (n = 38) or placebo (n = 33) microcurrent emitter. The study device was repetitively applied by each patient to the bilateral periorbital areas for 5 minutes. A visual analogue scale (VAS) for Pain severity was administered before, and 10 minutes after, treatment. Results Active microcurrent-treated patients had a reduction in mean Pain score from 5.63 pretreatment to 3.97 posttreatment (mean difference, 1.66; 95% confidence interval [CI], 1.20 to 2.12). Patients using the sham device also reported Sinus Pain reductions (mean difference, 0.91; 95% CI, 0.61 to 1.21). However, the active device demonstrated a significantly greater reduction in Pain compared to sham (0.75-point difference, p = 0.007). Notably, 23.7% of patients using the active device had a reduction of 3 or more points by VAS compared to 0% of sham device patients (p = 0.003). One minor occurrence of transient facial skin erythema was noted. Conclusion This trial suggests that treatment of rhinologic facial Pain using this noninvasive microcurrent device is safe and effective in providing rapid relief of nasal/Sinus Pain. Additional studies with longer term follow-up are warranted.